ProCE Banner Activity

CME

Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Multimedia
Watch this on-demand webcast from a live webinar where experts discuss the latest clinical trial data and their thoughts on the potential for antibody–drug conjugates in the care of patients with advanced NSCLC.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 23, 2021

Expiration: April 22, 2022

No longer available for credit.

Share

Faculty

Egbert F. Smit

Egbert F. Smit, MD, PhD

Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Paris-Saclay University
International Center for Thoracic Cancers
Villejuif, France

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Target Audience

This program is intended for global medical oncologists, pathologists and other healthcare professionals who care for patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the clinical rationale for assessing HER2, HER3, and TROP2 in the metastatic setting for NSCLC
  • Appraise the available clinical data on HER2-, HER3-, and TROP2-targeted antibody–drug conjugates in NSCLC
  • Plan therapeutic strategies for appropriate patients with HER2-altered NSCLC
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating novel HER2-, HER3-, and TROP2-targeted therapies in lung cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Egbert F. Smit, MD, PhD

Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

Egbert F. Smit, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Daiichi Sankyo, Merck, MSD, and Novartis; consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Merck, MSD, and Novartis; fees for non-CME/CE services from Daiichi Sankyo, Lilly, and MSD; and other financial support from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, and Roche/Genentech.

Faculty Disclosure

Primary Author

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Paris-Saclay University
International Center for Thoracic Cancers
Villejuif, France

David Planchard, MD, PhD, has disclosed that he has received funds for research support paid to his institution from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Lilly, MedImmune, Merck, Novartis, Novocure, Pfizer, Roche, Sanofi, and Taiho; consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Lilly, Merck, Novartis, Pfizer, Roche, and Samsung; and other financial support form AstraZeneca, Novartis, Pfizer, and Roche.

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena A. Yu, MD, has disclosed that she has received funds for research support paid to her institution from AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, and Pfizer; consulting fees from AstraZeneca, Blueprint, Daiichi Sankyo, and Janssen Oncology.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 23, 2021, through April 22, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to integrate new and emerging prognostic and predictive biomarkers into NSCLC treatment paradigms.